Metabolite quantification and high-field MRS in breast cancer

Ihab S. Haddadin, Adeka Mclntosh, Sina Meisamy, Curtis A Corum, Angela L. Styczynski Snyder, Nathaniel J. Powell, Michael Nelson, Douglas Yee, Michael Garwood, Patrick J Bolan

Research output: Contribution to journalReview articlepeer-review

122 Scopus citations


In vivo 1H MRS is rapidly developing as a clinical tool for diagnosing and characterizing breast cancers. Many in vivo and in vitro experiments have demonstrated that alterations in concentrations of choline-containing metabolites are associated with malignant transformation. In recent years, considerable efforts have been made to evaluate the role of 1H MRS measurements of total choline-containing compounds in the management of patients with breast cancer. Current technological developments, including the use of high-field MR scanners and quantitative spectroscopic analysis methods, promise to increase the sensitivity and accuracy of breast MRS. This article reviews the literature describing in vivo MRS in breast cancer, with an emphasis on the development of high-field MR scanning and quantitative methods. Potential applications of these technologies for diagnosing suspicious lesions and monitoring response to chemotherapy are discussed.

Original languageEnglish (US)
Pages (from-to)65-76
Number of pages12
JournalNMR in biomedicine
Issue number1
StatePublished - 2009


  • Breast
  • Cancer
  • Choline
  • High-field MR
  • MRS
  • Quantification


Dive into the research topics of 'Metabolite quantification and high-field MRS in breast cancer'. Together they form a unique fingerprint.

Cite this